Show simple item record

dc.contributor.authorJameson, Adam
dc.contributor.authorFylan, Beth
dc.contributor.authorBristow, Greg C.
dc.contributor.authorSagoo, G.S.
dc.contributor.authorDalton, C.
dc.contributor.authorCardno, A.
dc.contributor.authorSohal, J.
dc.contributor.authorMcLean, Samantha L.
dc.date.accessioned2021-10-06T09:12:27Z
dc.date.accessioned2021-10-11T13:44:03Z
dc.date.available2021-10-06T09:12:27Z
dc.date.available2021-10-11T13:44:03Z
dc.date.issued2021-09-22
dc.identifier.citationJameson A, Fylan B, Bristow GC et al (2021) What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings? Frontiers in Genetics. 12: 740216.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18618
dc.descriptionYesen_US
dc.description.abstractIn psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). These both contribute to poor levels of adherence. Pharmacogenetics (PGx) considers how genetic variation can influence an individual’s response to a drug. Pharmacogenetic testing is a tool that could aid clinicians when selecting psychotropic medications, as part of a more personalized approach to prescribing. This may improve the use of and adherence to these medications. Yet to date, the implementation of PGx in mental health environments in the United Kingdom has been slow. This review aims to identify the current barriers and enablers to the implementation of PGx in psychiatry and determine how this can be applied to the uptake of PGx by NHS mental health providers. A systematic searching strategy was developed, and searches were carried out on the PsychInfo, EmBase, and PubMed databases, yielding 11 appropriate papers. Common barriers to the implementation of PGx included cost, concerns over incorporation into current workflow and a lack of knowledge about PGx; whilst frequent enablers included optimism that PGx could lead to precision medicine, reduce ADRs and become a more routine part of psychiatric clinical care. The uptake of PGx in psychiatric care settings in the NHS should consider and overcome these barriers, while looking to capitalize on the enablers identified in this review.en_US
dc.description.sponsorshipBradford District Care NHS Foundation Trust in partnership with the University of Bradford; National Institute for Health Research (NIHR) Yorkshire and Humber Patient Safety Translational Research Centre (NIHR Yorkshire and Humber PSTRC); National Institute for Health Research Leeds in vitro Diagnostics Co-operative.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.3389/fgene.2021.740216en_US
dc.rights(c) 2021 The Authors. This is an Open Access article distributed under a Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/)en_US
dc.subjectMental health careen_US
dc.subjectPharmacogenetic testingen_US
dc.subjectBarriersen_US
dc.subjectEnablersen_US
dc.titleWhat Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?en_US
dc.status.refereedYesen_US
dc.date.Accepted2021-08-30
dc.typeArticleen_US
dc.type.versionPublished versionen_US
dc.date.updated2021-10-06T09:12:31Z
refterms.dateFOA2021-10-11T13:44:26Z
dc.openaccess.statusGolden_US


Item file(s)

Thumbnail
Name:
Jamesonbarriersandenablers.pdf
Size:
671.0Kb
Format:
PDF
Description:
jameson_et_al_2021

This item appears in the following Collection(s)

Show simple item record